EUCTR2005-001404-40-DK进行中（未招募）1 期
Cross-over multiple dose study assessing the analgesic efficacy and safety of oral GRT9906 PR compared to active comparator and placebo in subjects with painful polyneuropathy of mixed origin
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Painful polyneuropathy of mixed origin (diabetic, idiopathic, alcoholic or drug-induced neuropathy) with symptoms present for more than six months
- •- The pain must be distal and symmetric in the extremities and tendon reflexes must be reduced or absent
- •- No pain increase on activity
- •- Altered sensation distally on examination (touch; pin-prick; temperature)
- •- Abnormal conduction (motor nerve conduction velocity, distal motor latency, motor action potential amplitude, sensory nerve conduction velocity or sensory action potential amplitude) in at least two nerves, one of them being a leg nerve
- •- Average pain intensity of neuropathic pain over the last three days before randomization visit must be at least four points, using an 11-point NRS
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Known or suspected of being unable to comply with the study protocol and the use of the investigational medicinal products
- •- Evidence or history of alcohol, medication or drug dependency during the past 12 months
- •- Evidence or history of psychiatric illness including neurotic personality, anxiety disorder and depression needing treatment with antidepressants, severe senile dementia, Alzheimer's disease, history of seizures or suicide risk
- •- Cancer, poor medical status (e.g. NYHA class ? 3; Child classification for hepatic impairment >A (Pugh et al, 1973); decompensated chronic obstructive pulmonary disease) or, at the discretion of the investigator, clinical signs that raise concerns about subject's suitability for the study
- •- Subjects undergoing active treatment for cancer, are known to be infected with the HIV, hepatitis B or C, or being acutely and intensively immunosuppressed following transplantation
- •- Creatinine higher than 1.5 x upper limit of normal range
- •- ALT and/or AST higher than 2 x upper limit of normal range
- •- Pregnancy or nursing mother
- •- Clinically significant disease which in the investigator’s opinion may affect efficacy or safety assessments
- •- HbA1c > 12% at enrolment (discretion of the investigator)
- •- QT values of: QTcB females = 450 msec, QTcB males = 430 msec, uncorrected QT = 500 msec) at enrolment and/ or randomization
- •- Known contraindications/hypersensitivity to opioids, tramadol, zolpidem or paracetamol or definite or suspected allergy or hypersensitivity to drugs having a similar mechanism of action as the study drug
- •- Use of fentanyl transdermal system, buprenorphine sublingual or transdermal system with a half-life of more than 35 hours, ? 7 days prior to randomization
- •- Use of serotonergic drugs, drugs with the potential to prolong QT interval, CYP2D6 substrates, antiepileptic drugs, antiparkinson drugs, MAO inhibitors, neuroleptics or other drugs that may lower the seizure threshold, within less than five half-life times prior to randomization at least 7 days
- •- Use of any analgesics (incl. NSAIDs and COX2 inhibitors) other than the investigational product(s) and paracetamol as rescue medication or sedatives (with the exception of 5 mg zolpidem for a maximum of three days per week) within less than five half-life times prior to randomization at least 7 days
研究者
相似试验
进行中（未招募）
不适用
Cross-over multiple dose study assessing the analgesic efficacy and safety of oral GRT9906 PR compared to active comparator and placebo in subjects with painful polyneuropathy of mixed origiEUCTR2005-001404-40-DEGrünenthal GmbH
已完成
1 期
A study in healthy subjects to see the effects of the test medicine on the body when given in fed or fasted state as a multiple doseTransthyretin (TTR) Amyloidosis (ATTR)Digestive SystemISRCTN11628974Eidos Therapeutics, Inc.28
撤回
不适用
Multiple-Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Apixaban in Paediatric Subjects with an Indwelling Central Venous CatheterVein blockage due to clot10014523Venous ThromboembolismNL-OMON36556Bristol-Myers Squibb4
已完成
1 期
A Multiple Dose Study Evaluating the Pharmacokinetics of an Oral Tablet Formulation of BNC210 in Healthy VolunteersMental Health - Other mental health disordersTrauma and- stressor-related disordersMental Health - AnxietyAnxiety DisordersACTRN12621000125820Bionomics Limited10
已完成
不适用
A single dose, cross-over pharmacokinetic study comparing oral formulations of BNC210 in healthy male volunteersTrauma and stressor related disordersMental Health - AnxietyMental Health - Other mental health disordersAnxietyACTRN12618001197224Bionomics Limited6